U.S. Markets close in 2 hrs 18 mins
  • S&P 500

    4,419.25
    +62.80 (+1.44%)
     
  • Dow 30

    34,579.55
    +281.82 (+0.82%)
     
  • Nasdaq

    13,863.85
    +324.56 (+2.40%)
     
  • Russell 2000

    2,034.02
    +29.98 (+1.50%)
     
  • Crude Oil

    87.29
    +1.69 (+1.97%)
     
  • Gold

    1,829.80
    -22.70 (-1.23%)
     
  • Silver

    23.80
    -0.10 (-0.42%)
     
  • EUR/USD

    1.1297
    -0.0009 (-0.0791%)
     
  • 10-Yr Bond

    1.7780
    -0.0050 (-0.28%)
     
  • Vix

    28.24
    -2.92 (-9.37%)
     
  • GBP/USD

    1.3516
    +0.0010 (+0.0716%)
     
  • USD/JPY

    114.2900
    +0.4240 (+0.3724%)
     
  • BTC-USD

    37,826.47
    +501.12 (+1.34%)
     
  • CMC Crypto 200

    866.99
    +11.18 (+1.31%)
     
  • FTSE 100

    7,469.78
    +98.32 (+1.33%)
     
  • Nikkei 225

    27,011.33
    -120.01 (-0.44%)
     

Recro Pharma: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • REPH

Shares of Recro Pharma (NASDAQ:REPH) were flat in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 92.31% over the past year to ($0.25), which missed the estimate of ($0.16).

Revenue of $15,522,000 decreased by 50.34% year over year, which missed the estimate of $18,880,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Aug 10, 2020

View more earnings on REPH

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/3xhm9v2z

Price Action

52-week high: $19.21

52-week low: $3.99

Price action over last quarter: down 9.22%

Company Profile

Recro Pharma Inc is a contract development and manufacturing company. The company is engaged in the development, formulation, regulatory support, manufacturing, and packaging of oral solid dose drug products. Its product portfolio includes Ritalin LA; Focalin XR; Verelan PM, SR and Verapamil PM; Verapamil SR and Zohydro ER.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.